LEXINGTON, Mass., June 15, 2017 /PRNewswire/ -- Pulmatrix,
Inc. (NASDAQ: PULM), a
pharmaceutical company developing innovative inhaled drugs for
major lung diseases, has announced the appointment of
Amit D. Munshi to the Pulmatrix Board of
Directors. Mr. Munshi is currently President and CEO
of Arena Pharmaceuticals, a
biopharmaceutical company developing small molecule therapeutics
across a number of important conditions.
Mr. Munshi has extensive experience in biotechnology and
pharmaceuticals with an over 25 year record of
accomplishments. Prior to Arena Pharmaceuticals, Mr. Munshi
was previously the CEO of Epirus Biopharmaceuticals and held the
same role at Percivia LLC (sold to Johnson & Johnson).
From 2005 to 2010, Mr. Munshi was the Chief Business Officer and a
co-founder of Kythera Biopharmaceuticals, which was later acquired
by Allergan for $2.1 billion. Earlier
in his career, Mr. Munshi held roles of increasing responsibility
at Amgen globally in multiple product management, general
management and corporate development positions.
"I am excited to be joining the Board and helping in the
Company's next stage of growth," said Mr. Munshi. "As a lifelong
sufferer of pulmonary disease, I am deeply passionate about the
Company's mission and innovative approach to treating the lungs
with the iSPERSE technology."
"Mr. Munshi brings a breadth of experience in our industry
to the table including commercialization of products and business
development," said Pulmatrix CEO Robert W. Clarke,
Ph.D. "His previous
successes at biotechnology and pharmaceutical companies will
broaden the scope of our Board as we move into our next stage of
company growth and development of our pipeline
programs."
Mr. Munshi holds multiple undergraduate degrees from the
University of California, Riverside,
and an MBA from The Peter F. Drucker Graduate School at the
Claremont Graduate University. Mr
Munshi currently serves on the Board of Cytrellis Biosystems, Inc.,
a privately held company.
ABOUT PULMATRIX
Pulmatrix is a clinical stage biopharmaceutical company
developing innovative inhaled therapies to address serious
pulmonary disease using its patented iSPERSE™
technology. The Company's product pipeline is focused on
advancing treatments for lung diseases, including opportunities in
major pulmonary diseases through collaborations, like PUR0200, a
branded generic in clinical development for chronic obstructive
pulmonary disease (COPD) and PUR1900, a proprietary inhaled
itraconazole formulation that could benefit severe asthmatics and
patients with rare disease like cystic fibrosis. Pulmatrix
also has in-licensed a series of novel anti-inflammatory molecules
that are in development for COPD (PUR1800) and IPF (PUR5700).
Pulmatrix's product candidates are based on iSPERSE™, its
proprietary dry powder delivery platform, which seeks to improve
therapeutic delivery to the lungs by maximizing local
concentrations and reducing systemic side effects to improve
patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are
forward-looking and not statements of historical fact are
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements concerning the amount and use of proceeds the Company
expects to receive from the sale of the shares of common stock in
the registered direct offering, the closing of the transaction
described in this press release, which is subject to customary
conditions, and other statements that are not statements of
historical fact, and may be identified by words such as
"anticipates," "assumes," "believes," "can," "could," "estimates,"
"expects," "forecasts," "guides," "intends," "is confident that",
"may," "plans," "seeks," "projects," "targets," and "would," and
their opposites and similar expressions are intended to identify
forward-looking statements. The Company cautions that such
statements involve risks and uncertainties that may materially
affect the Company's results of operations. Such forward-looking
statements are based on the beliefs of management as well as
assumptions made by and information currently available to
management. Actual results could differ materially from those
contemplated by the forward-looking statements as a result of
certain factors, including, but not limited to, market and other
conditions, the satisfaction of customary closing conditions
related to the registered direct offering of common stock, the
ability to establish that potential products are efficacious or
safe in preclinical or clinical trials; the ability to establish or
maintain collaborations on the development of therapeutic
candidates; the ability to obtain appropriate or necessary
governmental approvals to market potential products; the ability to
obtain future funding for developmental products and working
capital and to obtain such funding on commercially reasonable
terms; the Company's ability to manufacture product candidates on a
commercial scale or in collaborations with third parties; changes
in the size and nature of competitors; the ability to retain key
executives and scientists; and the ability to secure and enforce
legal rights related to the Company's products, including patent
protection. A discussion of these and other factors, including
risks and uncertainties with respect to the Company, is set forth
in the Company's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K filed with the
Securities and Exchange Commission on March
10, 2017, as may be supplemented or amended by the Company's
Quarterly Reports on Form 10-Q. The Company disclaims any intention
or obligation to revise any forward-looking statements, whether as
a result of new information, future events or otherwise, except as
required by law.
Investor Contact
Robert Clarke, CEO
(781)
357-2333
rclarke@pulmatrix.com
William Duke,
CFO
(781)
357-2333
wduke@pulmatrix.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amit-d-munshi-joins-pulmatrixs-board-of-directors-300474769.html
SOURCE Pulmatrix, Inc.